Renal Oncocytoma
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Renal Oncocytoma

What is the definition of Renal Oncocytoma?
Renal oncocytoma is a benign (noncancerous) growth of the kidney. Renal oncocytoma generally do not cause any signs or symptoms and are often discovered incidentally (by chance) while a person is undergoing diagnostic imaging for other conditions. Some people with Renal oncocytoma will have abdominal or flank pain; blood in the urine; and/or an abdominal mass. Although these tumors can occur in people of all ages, they most commonly develop in men who are over age 50. The exact underlying cause of most isolated (single tumor affecting one kidney) Renal oncocytomas is unknown. Multiple and bilateral (affecting both kidneys) Renal oncocytomas sometimes occur in people with certain genetic syndromes such as tuberous sclerosis complex and Birt-Hogg-Dube syndrome.
What are the alternative names for Renal Oncocytoma?
  • Renal oncocytoma
  • Oncocytoma kidney
  • Oncocytoma renal
Who are the top Renal Oncocytoma Local Doctors?
Elite in Renal Oncocytoma
Elite in Renal Oncocytoma

Temple Faculty Practice Plan Inc

3509 N Broad St, 
Philadelphia, PA 
Languages Spoken:
English
Offers Telehealth

Alexander Kutikov is a Urologist in Philadelphia, Pennsylvania. Dr. Kutikov is rated as an Elite provider by MediFind in the treatment of Renal Oncocytoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Cystectomy.

Mohammad E. Allaf
Elite in Renal Oncocytoma
Oncology | Urology
Elite in Renal Oncocytoma
Oncology | Urology

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville

10803 Falls Road, Pavilion III STE 3300, Pavilion III STE 3300, 
Lutherville, MD 
Languages Spoken:
English, Arabic

Dr. Mohamad Allaf is Professor of Urology and Oncology, as well as Director of the Department of Urology and the Brady Urological Institute and Urologist-in-Chief of the Johns Hopkins Hospital. Dr. Allaf is a world renowned surgeon-scientist having performed more than 2,000 robotic procedures and published over 250 peer reviewed research papers in the field's best journals. As one of the busiest robotic radical prostatectomy surgeons in the world, he aims to achieve the best outcomes for his patients. Having trained with Dr. Patrick Walsh, Dr. Allaf has used Dr. Walsh's method of radical prostatectomy as the basis for his own anatomic method to this complex operation. Dr. Allaf is also amongst the leaders in kidney cancer surgery, having served on the American Urological Association Guideline Committee for Kidney Cancer. He led a team who performed the rigorous analysis to help inform the most recent guidelines that was funded by the Agency for Healthcare Research and Quality (AHRQ). He is best known for his ability to save the kidney and remove the tumor in patients with kidney tumors. Dr. Allaf runs a research endeavor aiming to decrease the morbidity associated with the treatment of cancer, and he has mentored numerous leaders in academic urology. He is actively involved in fund raising for research and education, and believes in expanding our base of support in order to advance our important mission. Dr. Allaf is rated as an Elite provider by MediFind in the treatment of Renal Oncocytoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Renal Oncocytoma, Prostate Cancer, Nephrectomy, and Prostatectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Wayne P. Tongco
Distinguished in Renal Oncocytoma
Distinguished in Renal Oncocytoma

Holston Medical Group- The Urology Clinic

2340 Knob Creek Rd, Ste 720, 
Johnson City, TN 
Languages Spoken:
English
Offers Telehealth

. Dr. Tongco is rated as a Distinguished provider by MediFind in the treatment of Renal Oncocytoma. His top areas of expertise are Renal Oncocytoma, UPJ Obstruction, Muscle Invasive Bladder Cancer, Ureteroscopy, and Reconstructive Urology Surgery.

What are the latest Renal Oncocytoma Clinical Trials?
A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

Summary: The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-ses...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Renal Cancer Detection With Liquid Biopsy

Summary: Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are sh...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center